Bulk Bevacizumab 400mg Supply New York | Indian Pharma Exporter

Bevatas 400mg Injection (Bevacizumab): Comprehensive Guide for Global Bulk Procurement

Are you seeking a reliable, high-capacity bulk supplier of Bevatas 400mg Injection? PRIMECARE IMPEX is a premier pharmaceutical exporter from India, specializing in temperature-controlled supply chain management for advanced oncology, monoclonal antibodies, and biosimilar therapies. We offer efficient, seamless end-to-end export logistics catering to medical networks, healthcare institutions, and wholesale distributors in New York (USA), Bristol (UK), Sydney (Australia), and Riyadh (Saudi Arabia).

Product Overview: Bevatas 400mg Injection

Manufactured by Intas Pharmaceuticals Ltd., Bevatas 400mg contains the active biosimilar substance Bevacizumab (400mg/16mL). It is a recombinant humanized monoclonal antibody belonging to the antineoplastic agent classification. It serves as a foundational therapeutic element in targeted anti-cancer drug protocols globally.

Primary Clinical Indications

• Metastatic Colorectal Cancer (mCRC): Administered alongside fluoropyrimidine-based chemotherapy.

• Advanced Non-Small Cell Lung Cancer (NSCLC): Utilized in platinum-based regimens for unresectable, advanced, or metastatic non-squamous variations.

• Glioblastoma Multiforme: Indicated as a treatment for recurrent malignant brain tumors.

• Metastatic Renal Cell Carcinoma (mRCC): Administered in combination with interferon-alfa.

• Gynecological Malignancies: Used to treat recurrent advanced epithelial ovarian, fallopian tube, primary peritoneal, and persistent metastatic cervical cancers.

Detailed Product Information

1. Mechanism of Action

Bevatas 400mg functions through specific angiogenesis inhibition. The active ingredient, Bevacizumab, selectively binds to the Vascular Endothelial Growth Factor (VEGF) protein ligand. By intercepting and neutralizing VEGF, the drug stops it from binding to its designated cell-surface receptors (VEGFR-1 and VEGFR-2) located on endothelial cells.

This directly prevents microvascular growth and blocks the formation of new blood vessels (neovascularization) that supply the tumor mass with oxygen, glucose, and systemic nutrients. Deprived of a blood supply, the tumor’s microenvironment degrades, halting tumor progression and increasing the therapeutic effectiveness of co-administered chemotherapy drugs.

2. Cold-Chain Storage & Technical Handling

• Temperature Range: Must be stored continuously in a validated pharmaceutical refrigerator between 2°C to 8°C (36°F to 46°F).

• Physical Protection: Do not freeze or shake the vial. Vigorous agitation can break down the complex monoclonal antibody proteins, rendering the injection ineffective. Store the vial inside its original outer commercial carton to protect it from direct light.

• Preparation: The solution contains no antimicrobial preservatives. It must be prepared, diluted, and administered strictly via aseptic clinical techniques by qualified medical personnel.

3. Secondary Effects & Clinical Risk Mitigation

While highly effective, Bevatas 400mg requires close clinical monitoring due to a distinct profile of manageable and severe side effects:

• Common Reactions: Nosebleeds (epistaxis), high blood pressure (arterial hypertension), alterations in taste, back pain, dry skin, and proteinuria (protein in the urine).

• Gastrointestinal Complications: Increased risk of gastrointestinal perforations and fistula formations.

• Wound Healing Interference: Bevacizumab slows down physiological wound healing. It should not be administered within 28 days before or after major surgery, including invasive dental operations.

• Hematologic Risks: Elevated risk of systemic bleeding events and arterial thromboembolic complications.

4. Commercial Advantages of Bevatas 400mg

• Higher Concentration Efficiency: The 400mg/16mL formulation allows clinical centers to manage high-dose oncology infusions efficiently with fewer individual vials.

• Broad-Spectrum Versatility: Proven therapeutic outcomes across gastrointestinal, pulmonary, renal, neurological, and gynecological cancers.

• Premium Biosimilar Affordability: Produced by Intas Pharmaceuticals, it offers a globally recognized, cost-effective alternative to high-cost innovator brands, delivering excellent financial margins for wholesale distributors.

5. Technical Documentation & Compliance

As a reliable exporter from India, PRIMECARE IMPEX backs every international shipment with complete certification files:

• Authentic Certificate of Analysis (COA) and batch release protocols.

• GMP Certified sourcing.

• Country of Origin Certification alongside detailed commercial invoices and packing indices.

• Active Cold-Chain Logistical Validation: Utilizing temperature-monitored, validated air cargo shippers to ensure the 2°C to 8°C window is meticulously maintained during transit

Prescription Medicine Warning & Legal Notice

⚠️ PRESCRIPTION MEDICINE: YES

Disclaimer: Bevatas 400mg Injection is a hazardous anti-cancer prescription medicine that must only be administered by qualified oncology specialists within a clinical hospital setting. The data presented here serves exclusively as a high-level informational resource for global B2B procurement agents, wholesalers, and medical distributors. It does not replace expert medical diagnosis, consultation, or therapeutic advice.

📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India

[GROUP OF PRIME CARE IMPEX PVT. LTD.]

🌐 Website: 

• 📧 Email: exports@ernestpharmaceuticals.com

• 📦 Business Type: Exporter | Bulk Supplier | Distributor

• 📲 WhatsApp: +91 9673008130

• 🔗 Instant Connection: Click Here to Chat on WhatsApp